Ellen Wittmack Donnelly

Ellen Wittmack Donnelly has a diverse work experience, primarily in the pharmaceutical and biotechnology industry. Ellen Wittmack currently serves as the Chief Executive Officer (CEO) of Abliva AB, a position they started in February 2021. Prior to that, they held various roles at Modus Therapeutics AB, including Director on the Board of Directors from June 2020 onwards and CEO from April 2017 to June 2020. Ellen Wittmack has also served as a Director on the Board of Directors at AlzeCure Pharma AB since May 2018.

In addition to their roles in these companies, Ellen has held leadership positions in other organizations. Ellen Wittmack was the CEO of Souvien Bio, leading the company from June 2020 to February 2021. Ellen Wittmack also served as the CEO of the Epigenetics Division of Juvenescence from June 2020 to February 2021.

Prior to these positions, Ellen had significant experience at Pfizer, where they held various roles from 2008 to 2016. These included serving as the Neuroscience Therapeutic Area Lead, Clinical Development and Operations, from April 2014 to November 2016. In this role, they were responsible for global clinical operations in the Neuroscience and Pain Therapeutic Area, achieving all corporate goals. Ellen Wittmack was also involved in driving innovation in drug development through various initiatives.

Before their time at Pfizer, Ellen worked at CombinatoRx as the Associate Director, Therapeutics, and Neuroscience Program Leader, from April 2007 to April 2008. Ellen Wittmack also worked as a Management Consultant at Leerink Swann & Co / MEDACorp from March 2005 to April 2007.

Ellen began their career as a PhD student in Pharmacology and Neuroscience at Yale University School of Medicine, where they studied from August 2000 to August 2004.

Ellen Wittmack Donnelly's education history includes a PhD and MS degree in Pharmacology and Neuroscience from Yale University School of Medicine, which they obtained from 2000 to 2004. Prior to that, they completed a Master of Forensic Science degree at The George Washington University from 1999 to 2000, specializing in Forensic Molecular Biology. Furthermore, they hold a Bachelor of Science degree from Iowa State University, which they acquired from 1992 to 1996. Their undergraduate studies focused on Genetics and French.